Afficher la notice abrégée
dc.contributor.author |
BEKHLOUF, Samira |
|
dc.date.accessioned |
2025-10-15T14:28:43Z |
|
dc.date.available |
2025-10-15T14:28:43Z |
|
dc.date.issued |
2025-06 |
|
dc.identifier.uri |
http://e-biblio.univ-mosta.dz/handle/123456789/29641 |
|
dc.description.abstract |
The medical analysis laboratory plays a vital role in the diagnosis of diseases, as the determination of biological parameters in humans requires a specific reference value on which to base the result that gives the clinician his or her first prognosis. However, this reference value, supplied by the commercial kit, is established by a national quality control laboratory in the supplier's country, according to the precise characteristics of the latter's population. This reference value has become a default reference value for populations whose characteristics are often very different from those of other countries.
The aim of our work is to assess the prevalence of thyroid disorders in men and women in the Mostaganem region from 2020 to May 2025. And to compare the pathological values with the reference values of the commercial Kit and those of the quality control serum developed within our population.
We carried out a retrospective study on two groups: the group of subjects with no thyroid disorders included 203 women and 122 men, and the second group of subjects with thyroid disorders (hypo or hyperthyroidism) included 307 women and 266 men. Within each group, subjects were divided into two age brackets: women aged between 25 and 39 years old, 40 and 45 years old; men aged between 25 and 49 years old and 50 years old and over.
We found that the reference intervals of the commercial Kit are not adapted to the biological, physiological and regional criteria of our population. During the investigation, we noticed a progressive increase in thyroid disturbances over the last five years (2020 to May 2025). We based our study on data collected in a private medical analysis laboratory.
The hypothesis of my objective is to compare our quality control serum with subjects with and without thyroid disorders from our population. |
en_US |
dc.language.iso |
fr |
en_US |
dc.subject |
TSH - FT4 - FT3 - Thyroid disturbances - Commercial Kit Reference Value - Quality Control Serum. |
en_US |
dc.title |
L’Intérêt du Sérum de Contrôle de Qualité en phase pré-Analytique dans l’Analyse de Paramètres Thyroïdiens dans la Localité de Mostaganem (Algérie) |
en_US |
dc.type |
Other |
en_US |
Fichier(s) constituant ce document
Ce document figure dans la(les) collection(s) suivante(s)
Afficher la notice abrégée